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Abstract
Objective: COVID-19 in people with diabetes is associated with a disproportionately 
worse prognosis. DKA is an acute complication of diabetes with a mortality rate of 
approximately 0.67%. Little is known about the natural history of DKA in the presence of 
COVID-19. This study aimed to explore the effects of COVID-19 on presentation, clinical 
course and outcome in patients presenting with DKA.
Design: Retrospective cohort study.
Methods: All patients treated for DKA between 1 March 2020 and 30 May 2020 were 
included. Patients were categorised as COVID-positive or COVID-negative based on the 
swab test. A pre-COVID group was established using data from 01 March 2019 to 30 May 
2019 as external control. Data regarding demographics, diabetes type, pH, bicarbonate, 
lactate, glucose, DKA duration, complications and outcome were collected.
Results: A total of 88 DKA episodes were included in this study. There was no significant 
difference in the severity or duration of DKA between the three groups. COVID-positive 
T1DM were more hyperglycaemic on admission compared to COVID-negative and pre-
COVID patients. There was an over representation of T2DM in COVID-positive patients 
with DKA than in pre-COVID or COVID-negative groups.
Conclusion: COVID-19 appears to influence the natural history of DKA differently in T1DM 
and T2DM. Patients with T1DM and COVID-19 presented with more hyperglycaemia  
(60 mmol/L (35.9–60.0) vs 31.4 mmol/L (28.0–39.1) vs 24 mmol/L (20.2–33.75), respectively). 
Patients with T2DM were unusually presenting in DKA when infected with COVID-19 with 
greater ICU need and higher mortality rates. A collaborative, multi-centre study is needed 
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People with diabetes are disproportionately affected 
by COVID-19. They are more likely to be admitted 
to the intensive care unit (ICU) compared to those 
without diabetes (1). A recent UK cohort study has also 
demonstrated two times greater mortality from COVID-19 
for those with type 2 diabetes (T2DM) and 3.5 times in 
those with type 1 diabetes mellitus (T1DM) compared to 
those without diabetes (2). Importantly, the majority of 
these deaths occurred in the elderly, and the absolute risk 
of death in the lower age groups was small (2).
Diabetic ketoacidosis (DKA) is an acute complication 
of diabetes characterised by hyperglycaemia, metabolic 
acidosis and ketosis (3, 4). The management of DKA 
includes aggressive re-hydration, insulin, and potassium 
monitoring (3, 5). The mortality of DKA is 0.67% 
outside the context of COVID-19 (6). Mortality rates 
associated with DKA in the presence of COVID-19 are 
unknown. Chamorro–Pareja  et al. report a mortality rate 
of 50% in patients with diabetes and COVID-19, while 
Alkundi   et  al. suggest that the development of DKA in 
patients with diabetes and COVID-19 is associated with 
a greater survival compared to those who do not develop 
DKA (7, 8).
Preliminary literature has suggested that an overall 
higher proportion of those with newly diagnosed T1DM 
is presented in DKA, with or without COVID-19 (9, 10). 
This perhaps represents delayed access of healthcare 
services. However, Beliard   et  al. found no difference 
in the proportion of those with newly diagnosed 
T1DM presenting with DKA between COVID-19 and 
non-COVID-19 groups (P = 0.81) (9). There remains 
uncertainty surrounding the clinical presentation and 
management of DKA in those with COVID-19. Case series 
have demonstrated that COVID-19 can precipitate DKA in 
those with pre-existing and undiagnosed diabetes (11, 12, 
13). It is clear larger-scale studies are needed to improve 
insight into the clinical characteristics and relationship 
between COVID-19 and DKA.
The aim of this study was to explore whether the 
presentation, clinical course, and outcome of DKA 
are altered in the presence of COVID-19 and whether 
there are any differences between patients with T1DM 
and T2DM.
Methods
We undertook a retrospective cohort study of all patients 
with DKA in our institution from 01 March 2020 to 
30 May 2020. Based on the SARS-coronavirus-PCR test 
results, patients were categorised into COVID-positive and 
COVID-negative groups. Further, to enable comparison 
with non-COVID associated DKA, we collected data on 
patients admitted with DKA from the corresponding 
period last year, that is, 01 March 2019 to 30 May 2019. 
People with other causes of acidosis (i.e. respiratory 
acidosis associated with hyperglycaemia) and mixed 
pictures of HHS and DKA were excluded from the study.
For all patients, we recorded demographic data, 
diabetes type, admission pH, bicarbonate, lactate, and 
glucose. Additionally, we also collected data on serum 
electrolytes, urea and creatinine at the time of admission, 
time to resolution of acidosis, time to resolution of 
ketosis, need for admission to ICU length of stay and 
final outcome.
DKA was diagnosed as per Joint British Diabetes 
Society guidelines in the UK (3). Rates of hypoglycaemia 
(glucose < 4 mmol/L), hypokalaemia (K+ < 3.5 mmol/L) 
and hyperkalaemia (K+ > 5.5 mmol/L) during DKA 
episodes were also recorded. In cases where the same 
patient was included twice in the data set for separate 
DKA episodes, the episodes were considered discrete if 
they were spaced 12 or more hours following biochemical 
resolution of the original DKA.
The data were analysed using GraphPad Prism 
Version 6.07. To determine the distribution of baseline 
characteristics, the Shapiro–Wilk test was used to test for 
normality. One-way ANOVA was used to compare the 
differences between groups. P-values provided are two-
tailed, and a value of <0.05 was considered as statistically 
significant. This report is part of an ongoing service 
improvement programme registered with the department 
of clinical governance in University Hospitals Birmingham 
NHS Foundation Trust to improve the care of people with 
DKA (Clinical Audit Registration and management system 
number: 12074).
Results
A total of 103 episodes were identified for the study. Nine 
cases were excluded as they had acidosis from respiratory 
failure associated with hyperglycaemia. A further six cases 
were excluded because the outcome for the COVID test 
was not available. Eighty-eight cases were included in the 
final analysis. These were further sub-classified into T1DM 
and T2DM. We are unsure of the type of diabetes in one 
patient who is currently undergoing further investigation 
(Table 1). Six COVID positive (all T2DM), eleven COVID 
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negative (eight T1DM, three T2DM), and one pre-COVID 
(T2DM) had hypertension as a comorbidity. Six patients 
in COVID-positive and one person in COVID-negative 
group were on SGLT2 inhibitors; none of the people in 
the pre-COVID period were on this class of drug.
Compared to the other two groups, COVID-positive 
patients were older, mainly driven by the number of 
T2DM patients in this group. Across all groups, there 
was a slight male preponderance. There was also a higher 
proportion of COVID-positive T2DM on treatment 
with sodium glucose transporter 2 inhibitors (SGLT2-i) 
(Table 1).
There was no significant difference in the severity 
of DKA at presentation in terms of pH, bicarbonate, 
glucose, lactate and serum osmolality. There was also no 
significant difference between the groups for the DKA 
duration (Fig. 1A).
COVID-positive patients with T1DM were more 
hyperglycaemic compared to COVID-negative and pre-
COVID patients at admission (60 mmol/L (35.9–60.0) 
vs 31.4 mmol/L (28.0–39.1) vs 24 mmol/L (20.2–33.75), 
respectively). There was, however, no difference in pH, 
bicarbonate, lactate, and serum osmolality on admission 
between the three groups (Fig. 1B). Also, there was no 
significant difference between the three groups for the 
fixed rate i.v. Also, there was no significant difference in 
the fixed rate of i.v. insulin infusion during DKA (COVID 
positive (n = 6/20): 7.5 units/h (5.6–9.1) vs COVID negative 
(n = 26/31): 7 units/h (5.6–7.1) vs pre-COVID (n = 37/37): 
6 units/h (5.2–7.6)).
Table 1 Characteristics of all patients included in the study analysis.
COVID positive COVID negative Pre-COVID
All patients
 n 20 31 37
 T2DM, n 15/20 2/31 8/37
 Median length of hospitalisation, days (IQR) 7.0 (5.2–19.5) 5 (1.9–8.2) 4.9 (2.3–11.4)
 Median age, years (IQR) 59.8 (43.0–69.0) 50.9 (33.3–60.9) 31 (24.4–54.2)
 Male gender, n 14/20 19/31 22/37
 Median weight, kg (IQR) 76.2 (51.7–86.1) 65.4 (58.9–70.7) 63 (55.1–75.0)
 Median height, m (IQR) 1.73 (1.7–1.8) 1.6 (1.6–1.7) 1.7 (1.6–1.8)
 SGLT2 inhibitors, n 6/20 1/31 0/37
 ACEi/ARB, n 6/20 1/31 1/37
 ITU admission, n 6/20 4/31 0/37
 Deaths, n 4/20 1/31 0/37
 Episodes of hypokalaemia, n (IQR) 0 (0–0) 1 (0–4) 0 (0–0)
 Episodes of hyperkalaemia, n (IQR) 0 (0–1) 0 (0–1) 0 (0–0)
T1DM
 n 5 29 29
 Median length of hospitalisation, days (IQR) 4.5 (4.3–4.8) 5 (1.9–8.0) 3.6 (2.1–7.8)
 Median age, years (IQR) 30.9 (27.0–45.0) 47.4 (33.2–58.9) 26.5 (23.9–49.8)
 Male gender, n 2/5 17/29 16/29
 Median weight, kg (IQR) 67.9 (49.4–86.7) 65.7 (58.5–71.1) 60.7 (55.1–71.1)
 Median height, m (IQR) 1.7 (1.7–1.8) 1.6 (1.6–1.7) 1.7 (1.6–1.7)
 SGLT2 inhibitors, n 0/5 0/29 0/29
 ACEi/ARB, n 0/5 1/29 0/29
 ITU admission, n 2/5 4/29 0/29
 Deaths, n 0/5 1/29 0/29
 Episodes of hypokalaemia, n (IQR) 0 (0–2) 0.5 (0–3) 0 (0–0)
 Episodes of hyperkalaemia, n (IQR) 1 (0–1) 0 (0–0.75) 0 (0–0)
T2DM
 n 15 2 8
 Median length of hospitalisation, days (IQR) 10.0 (6.0–20.0) 10.8 (7.4–14.2) 11.2 (8.1–18.7)
 Median age, years (IQR) 63.0 (58.8–75.0) 72.7 (70.9–74.6) 58.0 (50.5–70.4)
 Male gender, n 12/15 2/2 6/8
 Median weight, kg (IQR) 76.2 (64.8–83.4) 60.0 (60.0–60.0) 98.0 (59.4–114.0)
 Median height, m (IQR) 1.7 (1.7–1.7) 1.7 (1.7–1.7) 1.8 (1.7–1.8)
 SGLT2 inhibitors, n 6/15 1/2 0/8
 ACEi/ARB, n 6/15 0/2 1/8
 ITU admission, n 4/15 0/2 1/8
 Deaths, n 4/15 0/2 0/8
 Episodes of hypokalaemia, n (IQR) 0 (0–0) 2.5 (1–4) 0 (0–0.75)
 Episodes of hyperkalaemia, n (IQR) 0 (0–1) 0 (0–0) 0 (0–0)
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In patients with T2DM, no major differences were 
seen between groups in pH, bicarbonate, glucose, lactate 
and serum osmolality on admission or duration of DKA 
(Fig. 1C).
COVID-negative patients had more episodes of 
hypokalaemia and hyperkalaemia during DKA compared 
to other two groups (Hypokalaemia: COVID-negative vs 
COVID-positive group: P = 0.0037; COVID-negative vs 
pre-COVID group: P = 0.0005; Hyperkalaemia: COVID-
negative vs COVID-positive group: P = 0.1026; COVID-
negative vs pre-COVID group: P = 0.0043). There was no 
significant difference between the number of episodes 
of hypokalaemia in the COVID-positive compared 
to the pre-COVID group (P > 0.9999). In patients 
with T2DM, hypokalaemia was more common in 
COVID-negative patients (COVID-negative vs 
Figure 1
Differences in the duration and severity of DKA (pH, bicarbonate, glucose, lactate and serum osmolality) between three groups in all patients (A), T1DM 
(B) and T2DM (C).
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COVID-positive group: P = 0.0016; COVID-negative 
vs pre-COVID group: P = 0.0052; COVID-positive vs 
pre-COVID: P = 0.8602) (Table 1).
Six of the 20 COVID-positive patients and 4 of the 
31 COVID-negative patients required admission to ICU. 
Zero of the 37 patients in the pre-COVID period required 
admission to ICU. Five patients (1/31 COVID-negative 
and 4/20 COVID-positive) died during the admission. The 
COVID-negative patient had T1DM and all four COVID-
positive patients who died had T2DM. Of the four T2DM 
COVID-positive patients, only one had been admitted to 
ICU. In patients with T2DM, all of the deaths occurred in 
the COVID-positive group. No deaths were noted in the 
cohort of patients from the pre-COVID period.
Discussion
Our result did not identify any effect of COVID-19 on 
the overall presentation or duration of DKA. However, 
differences emerged when T1DM and T2DM subtypes 
were analysed individually. Compared to those who 
were COVID-negative, COVID-positive patients with 
T1DM presented with significantly higher blood glucose. 
This perhaps reflects delayed presentation and access to 
healthcare services, a notion discussed by Beliard et  al. 
and Kamrath   et  al. (9, 10). They also tended to have a 
longer recovery time compared to the two other groups. 
Such differences were not apparent in those with T2DM. 
However, COVID-positive patients with T2DM were more 
likely to need ICU with higher mortality rates. There was 
also a notable increase in DKA in the T2DM patient group 
– not seen in either of the COVID-negative groups.
A particular strength of our study is that we have 
compared the presentation and outcomes in COVID-
negative patients and also those from pre-COVID period 
providing a realistic measure of the impact of COVID-19 
on the natural history of DKA. Further, we only included 
those meeting the criteria for DKA and excluded those 
with hyperosmolar hyperglycaemic state (HHS), mixed 
HHS and DKA, and acidosis due to other causes. Our study 
has several limitations. Given that the data represent 
admissions with DKA over a short period, our sample size 
was small. Retrospective nature of the study and missing 
data further limited our ability to undertake extended 
analyses and explore other associations. The false negative 
rates in the SARS-coronavirus-PCR test could have further 
impacted the results of our study (14).
The findings of our study need to be interpreted 
in the context of available evidences (15, 16, 17, 18). 
COVID-19 as a trigger for DKA has been reported in 
a number of studies (19, 20, 21). In contrast, there are 
very few studies that have reported on the severity or 
outcomes in patients presenting with DKA. Studies on 
patients who presented with DKA and COVID-19 have 
reported significantly prolonged ketosis and duration of 
DKA for up to 35 h (22, 23). The duration of ketosis in our 
study was much shorter (15–17 h) and similar in all three 
groups suggesting the duration of DKA is not impacted 
by COVID-19 status. The heterogeneity of these results 
could be due to the differences in the sample sizes and 
the characteristics of comparator groups. Other factors 
such as severity of the COVID-19 itself and associated 
co-morbidities may also have an effect. Moreover, as 
observed in our cohort, differences may exist between 
those with T1DM and T2DM and this differentiation 
needs to be studied further.
Consistent with the observations of Armeni et al. (22), 
there was an over presentation of T2DM in our cohort. 
This may be because patients with T2DM are likely to be 
older and at a greater risk of severe disease with COVID-19. 
Additionally, it would also reflect the demographics of 
population served. Of these, six (n = 6/15) of COVID-
positive and one (n = 1/2) COVID-negative were on 
SGLT2-i. The risk of DKA in patients on SGLT2-i is well 
recognised (24, 25). Current guidance recommends 
discontinuation of these agents in the setting of 
acute illness and highly pertinent in COVID-positive 
patients (26).
As was observed in other studies, proportionately 
more COVID-positive patients were admitted to ICU with 
higher mortality compared to the COVID-negative group, 
particularly in those with T2DM. In comparison with the 
data from Armeni et al. (22), our mortality rate was higher 
(n = 4/20 vs n = 1/11). However, it is important to note that 
these data might not represent the true mortality rate for 
patients with DKA and COVID-19 given the small sample 
sizes. Moreover, in our study population, those who were 
COVID-positive had a median age of 59.8 (43.0–69.0), 
significantly younger than those people who were most 
likely to die as demonstrated by Barron et al. (2). Larger 
studies with bigger cohort sizes are needed to give a better 
estimate on this rate. Our results also suggest that the 
higher mortality rate in patients with T1DM infected with 
COVID-19 is not attributable to DKA.
Careful monitoring of potassium due to the risk of 
hypokalaemia was also highlighted (23). We did not 
observe increased rates of kalaemic complications in 
our DKA and COVID-positive group. On the contrary, 
COVID-negative cohort had higher rates of hyper- and 
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hypokalaemia compared to COVID-positive and pre-
COVID groups. Although we did not observe a significant 
difference for the insulin requirements during DKA 
between the three groups, we still feel this is the most 
plausible explanation for kalaemic changes during DKA 
and we hope this can be answered in future larger cohorts.
Our study is an important contribution in an area 
where there is a paucity of information and while the 
findings of our study are indicative, they are not definitive. 
On the other hand, our findings highlight a greater need 
for studies involving larger cohorts and structured data 
collection. Also, factors such as comorbidity, pre-admission 
medications and disease control need to be factored in the 
assess their impact of severity and morbidity associated 
with DKA. Considering rates of COVID-19 can vary 
greatly, and therefore the likelihood of DKA presentations 
also variable, a collaborative approach involving multiple 
centres is required.
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